A patient with no family history of hereditary hemorrhagic telangiectasia presents with a pathogenic variant of BPMR2 and pulmonary arteriovenous malformations. Read the full research in the May issue to learn more: https://hubs.la/Q01Q5W4R0 #JournalCHEST #MedEd | American College of Chest Physicians

For patients with hereditary hemorrhagic telangiectasia, no approved therapies exist. The efficacy and safety of pomalidomide, a thalidomide derivative, in treating HHT is unknown. Research findings are summarized in a new Quick Take video. https://nej.md/3MUk9VW | The New England Journal of Medicine